TY - JOUR
T1 - Determination of Free 25(OH)D Concentrations and Their Relationships to Total 25(OH)D in Multiple Clinical Populations
AU - Schwartz, Janice B.
AU - Christopher Gallagher, J.
AU - Jorde, Rolf
AU - Berg, Vivian
AU - Walsh, Jennifer
AU - Eastell, Richard
AU - Evans, Amy L.
AU - Bowles, Simon
AU - Naylor, Kim E.
AU - Jones, Kerry S.
AU - Schoenmakers, Inez
AU - Holick, Michael
AU - Orwoll, Eric
AU - Nielson, Carrie
AU - Kaufmann, Martin
AU - Jones, Glenville
AU - Bouillon, Roger
AU - Lai, Jennifer
AU - Verotta, Davide
AU - Bikle, Daniel
N1 - Funding Information:
Financial Support: The project received financial support in part by Future Diagnostics, BV, and Diasource Inc. (J.B.S.). Original research investigations were supported as follows: US support (National Institutes of Health unless otherwise stated): R21 AG 041660 (J.B.S., J.L.), P30 DK026743 (J.L.), R01 AR050023(J.L.),R01AG15982(J.B.S.),R56AG15982(J.B.S.), U01 AG027810 (E.O.), U01 AG042124 (E.O.), U01 AG042139 (E.O.), U01 AG042140 (E.O.), U01 AG042143 (E.O.), U01 AG042145 (E.O.), U01 AG042168 (E.O.), R01-AG28168 (E.O., J.C.G.), U01 AR066160 (E.O.), UL1 TR000128 (E.O.), P41GM103493, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) K01 AR062655, NIAMS R01 AR063910, T32 DK007674-20, an American College of Gastroenterology Clinical Research Award (J.L.), Department of Defense (W81XWH-07-1-201; J.C.G.), and Department of Energy (contract DE-AC05-76RL0 1830). United Kingdom support: Department of Health (policy research program 024/0052;R.E.)andbytheSheffieldNationalInstituteforHealth Research Clinical Research Facility (R.E.), the Medical Research Council (MRC; R.E.), and the Department for International Development (DFID; (R.E.) [under the MRC/DFID Concordat; MRC unit programs U105960371 (R.E.) and U123261351; I.S., R.E.]. MC-A760-5QX00 (I.S.) and DFID (under MRC/DFID Concordat agreement), Research Foundation Flanders (G. 0858.11; I.S.)andKULeuven(GOA15/0/01;R.B.).InNorway:NovoNordisk foundation (grant number R195-A16126; R.R.), North Norway RegionalHealthAuthorities(grantnumber6856/SFP1029-12;R.J.), UiT The Arctic University of Norway (R.J.), the Norwegian Diabetes Association (R.J.), and the Research Council of Norway (grant number 184766).
Publisher Copyright:
© 2018 Endocrine Society.
PY - 2018/9/1
Y1 - 2018/9/1
N2 - Context: The optimal measure of vitamin D status is unknown. Objective: To directly measure circulating free 25-hydroxyvitamin D [25(OH)D] concentrations and relationships to total 25(OH)D in a clinically diverse sample of humans. Design: Cross-sectional analysis. Setting: Seven academic sites. Patients: A total of 1661 adults: healthy (n = 279), prediabetic (n = 479), outpatients (n = 714), cirrhotic (n = 90), pregnant (n = 20), nursing home resident (n = 79). Interventions: Merge research data on circulating free 25(OH)D (directly-measured immunoassay), total 25(OH)D (liquid chromatography/tandem mass spectrometry), D-binding protein [DBP; by radial (polyclonal) immunodiffusion assay], albumin, creatinine, intact parathyroid hormone, and DBP haplotype. Main outcome measures: Distribution of free 25(OH)D (ANOVA with Bonferroni correction for post hoc comparisons) and relationships between free and total 25(OH)D (mixed-effects modeling incorporating clinical condition, DBP haplotype with sex, race, estimated glomerular filtration rate (eGFR), body mass index (BMI), and other covariates). Results: Free 25(OH)D was 4.7 ± 1.8 pg/mL (mean ± SD) in healthy persons and 4.3 ± 1.9 pg/mL in outpatients, with levels of 0.5 to 8.1 pg/mL and 0.9 to 8.1 pg/mL encompassing 95% of healthy persons and outpatients, respectively. Free 25(OH)D was higher in patients with cirrhosis (7.1 ± 3.0 pg/mL; P < 0.0033) and nursing home residents (7.9 ± 2.1 pg/mL; P < 0.0033) than in other groups and differed between whites and blacks (P < 0.0033) and between DBP haplotypes (P < 0.0001). Mixed-effects modeling of relationships between free and total 25(OH)D identified clinical conditions (patients with cirrhosis . nursing home residents . patients with prediabetes . outpatients . pregnant women) and BMI (lesser effect) as covariates affecting relationships but not eGFR, sex, race, or DBP haplotype. Conclusions: Total 25(OH)D, health condition, race, and DBP haplotype affected free 25(OH)D, but only health conditions and BMI affected relationships between total and free 25(OH)D. Clinical importance of free 25(OH)D needs to be established in studies assessing outcomes.
AB - Context: The optimal measure of vitamin D status is unknown. Objective: To directly measure circulating free 25-hydroxyvitamin D [25(OH)D] concentrations and relationships to total 25(OH)D in a clinically diverse sample of humans. Design: Cross-sectional analysis. Setting: Seven academic sites. Patients: A total of 1661 adults: healthy (n = 279), prediabetic (n = 479), outpatients (n = 714), cirrhotic (n = 90), pregnant (n = 20), nursing home resident (n = 79). Interventions: Merge research data on circulating free 25(OH)D (directly-measured immunoassay), total 25(OH)D (liquid chromatography/tandem mass spectrometry), D-binding protein [DBP; by radial (polyclonal) immunodiffusion assay], albumin, creatinine, intact parathyroid hormone, and DBP haplotype. Main outcome measures: Distribution of free 25(OH)D (ANOVA with Bonferroni correction for post hoc comparisons) and relationships between free and total 25(OH)D (mixed-effects modeling incorporating clinical condition, DBP haplotype with sex, race, estimated glomerular filtration rate (eGFR), body mass index (BMI), and other covariates). Results: Free 25(OH)D was 4.7 ± 1.8 pg/mL (mean ± SD) in healthy persons and 4.3 ± 1.9 pg/mL in outpatients, with levels of 0.5 to 8.1 pg/mL and 0.9 to 8.1 pg/mL encompassing 95% of healthy persons and outpatients, respectively. Free 25(OH)D was higher in patients with cirrhosis (7.1 ± 3.0 pg/mL; P < 0.0033) and nursing home residents (7.9 ± 2.1 pg/mL; P < 0.0033) than in other groups and differed between whites and blacks (P < 0.0033) and between DBP haplotypes (P < 0.0001). Mixed-effects modeling of relationships between free and total 25(OH)D identified clinical conditions (patients with cirrhosis . nursing home residents . patients with prediabetes . outpatients . pregnant women) and BMI (lesser effect) as covariates affecting relationships but not eGFR, sex, race, or DBP haplotype. Conclusions: Total 25(OH)D, health condition, race, and DBP haplotype affected free 25(OH)D, but only health conditions and BMI affected relationships between total and free 25(OH)D. Clinical importance of free 25(OH)D needs to be established in studies assessing outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85052731320&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052731320&partnerID=8YFLogxK
U2 - 10.1210/jc.2018-00295
DO - 10.1210/jc.2018-00295
M3 - Article
C2 - 29955795
AN - SCOPUS:85052731320
SN - 0021-972X
VL - 103
SP - 3278
EP - 3288
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 9
ER -